Table 4.

Study outcomes

Primary endpoint	The change in hb concentrations from POD1 to POD14
Secondary endpoints	Changes in Hb concentrations from POD1 to POD5 and from POD1 to POD35 Reticulocyte count and reticulocyte haemoglobin content on POD1-3, POD5, POD7, POD14 and POD35 The percentage of correction of anaemia (elevation of Hb>20 g/L or Hb≥120 g/L) at POD5, POD14 and POD35 Changes in serum iron from POD1 to POD5, from POD1 to POD14 and from POD1 to POD35 Changes in ferritin from POD1 to POD5, from POD1 to POD14 and from POD1 to POD35 Changes in TSAT from POD1 to POD5, from POD1 to POD14 and from POD1 to POD35 Changes in sTFR from POD1 to POD5, POD1 to POD14 and from POD1 to POD35 Allogeneic red blood cell transfusion rates at POD5, POD14 and POD35 Quality of life as assessed by the EQ-5D, FACIT-fatigue and Barthel Index questionnaire at POD5, at POD14, at POD35 Length of hospital stay
Safety endpoints	Incidence of adverse events Incidence of postoperative infection

EQ-5D questionnaire, European Quality of Life-5 Dimensions; FACIT-fatigue, Functional Assessment of Chronic Illness Therapy – Fatigue Scale; Hb, haemoglobin; POD, postoperative day; sTFR, serum transferrin receptor; TSAT, transferrin saturation.